Shopping Cart 0
Cart Subtotal
USD 0

AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

AC Immune SA (ACIU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune's product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company's lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer's disease. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA Key Recent Developments

May 02,2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

Apr 05,2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease

Mar 20,2018: AC Immune reports full-year 2017 financial results-successful first year as a public company

Feb 06,2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference

Dec 01,2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

AC Immune SA-Key Facts 5

AC Immune SA-Key Employees 6

AC Immune SA-Key Employee Biographies 7

AC Immune SA-Major Products and Services 8

AC Immune SA-History 9

AC Immune SA-Company Statement 10

AC Immune SA-Locations And Subsidiaries 11

Head Office 11

Section 2-Company Analysis 12

AC Immune SA-Business Description 12

AC Immune SA-Corporate Strategy 13

AC Immune SA-SWOT Analysis 14

SWOT Analysis-Overview 14

AC Immune SA-Strengths 14

AC Immune SA-Weaknesses 16

AC Immune SA-Opportunities 17

AC Immune SA-Threats 18

AC Immune SA-Key Competitors 19

Section 3-Company Financial Ratios 20

Financial Ratios-Capital Market Ratios 20

Financial Ratios-Annual Ratios 21

Performance Chart 23

Financial Performance 23

Financial Ratios-Ratio Charts 24

Section 4-Company's Lifesciences Financial Deals and Alliances 25

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

AC Immune SA, Recent Deals Summary 27

Section 5-Company's Recent Developments 28

May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update 28

Apr 05, 2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease 30

Mar 20, 2018: AC Immune reports full-year 2017 financial results-successful first year as a public company 31

Feb 06, 2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference 34

Dec 01, 2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases 36

Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update 37

Oct 03, 2017: AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinsons Research 39

Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases 40

Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results 41

Jul 10, 2017: AC immune provides seven updates on its pipeline and technology at the alzheimer's association international conference 43

Section 6-Appendix 44

Methodology 44

Ratio Definitions 44

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

AC Immune SA, Performance Chart (2013-2017) 24

AC Immune SA, Ratio Charts 25

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 27


List Of Table

List of Tables

AC Immune SA, Key Facts 6

AC Immune SA, Key Employees 7

AC Immune SA, Key Employee Biographies 8

AC Immune SA, Major Products and Services 9

AC Immune SA, History 10

AC Immune SA, Key Competitors 20

AC Immune SA, Ratios based on current share price 21

AC Immune SA, Annual Ratios 22

AC Immune SA, Annual Ratios (Cont...1) 23

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27

AC Immune SA, Recent Deals Summary 28

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

AC Immune SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Axon Neurosciences

Araclon Biotech

AbbVie

AC Immune SA (ACIU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune's product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company's lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer's disease. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA Key Recent Developments

May 02,2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

Apr 05,2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease

Mar 20,2018: AC Immune reports full-year 2017 financial results-successful first year as a public company

Feb 06,2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference

Dec 01,2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

AC Immune SA-Key Facts 5

AC Immune SA-Key Employees 6

AC Immune SA-Key Employee Biographies 7

AC Immune SA-Major Products and Services 8

AC Immune SA-History 9

AC Immune SA-Company Statement 10

AC Immune SA-Locations And Subsidiaries 11

Head Office 11

Section 2-Company Analysis 12

AC Immune SA-Business Description 12

AC Immune SA-Corporate Strategy 13

AC Immune SA-SWOT Analysis 14

SWOT Analysis-Overview 14

AC Immune SA-Strengths 14

AC Immune SA-Weaknesses 16

AC Immune SA-Opportunities 17

AC Immune SA-Threats 18

AC Immune SA-Key Competitors 19

Section 3-Company Financial Ratios 20

Financial Ratios-Capital Market Ratios 20

Financial Ratios-Annual Ratios 21

Performance Chart 23

Financial Performance 23

Financial Ratios-Ratio Charts 24

Section 4-Company's Lifesciences Financial Deals and Alliances 25

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

AC Immune SA, Recent Deals Summary 27

Section 5-Company's Recent Developments 28

May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update 28

Apr 05, 2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease 30

Mar 20, 2018: AC Immune reports full-year 2017 financial results-successful first year as a public company 31

Feb 06, 2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference 34

Dec 01, 2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases 36

Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update 37

Oct 03, 2017: AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinsons Research 39

Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases 40

Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results 41

Jul 10, 2017: AC immune provides seven updates on its pipeline and technology at the alzheimer's association international conference 43

Section 6-Appendix 44

Methodology 44

Ratio Definitions 44

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

AC Immune SA, Performance Chart (2013-2017) 24

AC Immune SA, Ratio Charts 25

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 27


List Of Table

List of Tables

AC Immune SA, Key Facts 6

AC Immune SA, Key Employees 7

AC Immune SA, Key Employee Biographies 8

AC Immune SA, Major Products and Services 9

AC Immune SA, History 10

AC Immune SA, Key Competitors 20

AC Immune SA, Ratios based on current share price 21

AC Immune SA, Annual Ratios 22

AC Immune SA, Annual Ratios (Cont...1) 23

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27

AC Immune SA, Recent Deals Summary 28

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

AC Immune SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Axon Neurosciences

Araclon Biotech

AbbVie